research-labs

Gallery

Figure 3 (F)Mechanisms and activated signal transduction pathways in diabetes associated breast cancer risk and progression. For details, please see publication at https://doi.org/10.1016/j.ctrv.2018.08.004

                                   

Figure 1

Mechanisms of chemoresistance in breast cancers. For details, please see publication at https://doi.org/10.3390/cancers12092482


Figure 1[1]

Endothelial cell signaling in promoting tumor angiogenesis. For details, please see publication at https://doi.org/10.3390/biom10020191


Figure 2 (Final)

Metabolic components of drug resistance in breast cancer and anticancer drugs/or combinations treatment targeting tumor glucose metabolism. For details, please see publication at https://doi.org/10.3390/cancers12082252


Figure 2 

Molecular mediators (A) and effects (B) of the anti-cancer actions of metformin. For details, please see publication at https://doi.org/10.3390/cancers12092482


Figure 1 (10th Feb 2021)Bidirectional relationship of diabetes vs. COVID-19 and the potential benefits of the antidiabetic drug metformin. For details, please see publication at https://doi.org/10.1371/journal.ppat.1009634


Figure 2 (09th Feb 2021)

RAAS/SARS-CoV-2 axis in exaggerated immune response and acute pancreatic injury. For details, please see publication at https://doi.org/10.1371/journal.ppat.1009634


Figure-2 (revised 27 Jan 2021)Multiple benefits of metformin treatment against SARS-CoV-2 infection. For details, please see publication at https://doi.org/10.1016/j.tim.2021.03.004



IMG_5279

Ca2+-signals after the application of an anti-cancer drug